VCYT — Veracyte, Inc.

Summary of Veracyte (VCYT) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $141 million, a 19% increase year-over-year.
• Full Year Revenue: $517 million, also a 16% increase.
• Testing Revenue: $135.8 million in Q4, up 21% year-over-year.
• Adjusted EBITDA Margin: 30.1% in Q4, with a full-year margin of 27.6%, exceeding the 25% target set for 2026.
• Cash Flow: Generated $52.6 million from operations, ending the quarter with $412.9 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Continued strong performance in core testing business, with Decipher volume growing 21% and Afirma growing 12% in Q4.
• Significant milestones achieved in 2025, including the launch of Decipher for metastatic patients and the transition of Afirma to a more scalable v2 transcriptome platform.
• Positive outcomes from the OPTIMA PRELIM study for Prosigna and completion of enrollment for the NIGHTINGALE lung cancer study.
• Plans for two major product launches in 2026: TrueMRD for muscle invasive bladder cancer and Prosigna for early-stage breast cancer.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $570 million to $582 million, reflecting 10% to 13% growth year-over-year.
• Testing Revenue Growth: Expected to be 14% to 16%, with Afirma growth in the mid- to high single digits and Decipher growth around 20%.
• Anticipated adjusted EBITDA margin of approximately 25% for 2026, with Q1 expected to be lower due to seasonal expenses.

4. Bad News, Challenges, or Points of Concern

• Q1 adjusted EBITDA margin is expected to be lower than the annual guidance due to typical seasonal expense increases and prior period collections not being included in guidance.
• Competitive pressures are evident in the Decipher market, with competitors investing heavily in their assays, although Veracyte maintains confidence in Decipher's growth trajectory.
• The company is cautious about the potential impact of new product launches on profitability, indicating a willingness to invest more if necessary to capture market share.

5. Notable Q&A Insights

• Management expressed strong conviction in their 2026 guidance, citing factors that could drive revenue to the high end of the range, including prior period collections and volume outperformance.
• There was discussion about the potential for Decipher Bladder to expand into earlier-stage treatment decision-making, contingent on further clinical evidence.
• The reimbursement strategy for TrueMRD involves pursuing two separate codes for initial and follow-up testing, with ongoing negotiations for pricing.
• Management emphasized a focus on customer experience for MRD in 2026, with revenue contributions expected to be more significant in 2027 and beyond.

Overall, Veracyte demonstrated solid financial performance in 2025, with a strong outlook for 2026 driven by strategic product launches and continued growth in existing testing services, despite facing competitive pressures and the need for careful management of operational expenses.